]>A Population-Based Clinical Trial of Irinotecan and Carboplatin : Figure 2
458528.fig.002
Figure 2: Cumulative percent of patients experienced dose-limiting toxicity (DLT) with increasing dose levels of irinotecan and carboplatin (N = 50).